Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.70 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092222 | 0.89 | PIK3CA (0.79) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL635497 | 0.88 | PIK3CA (0.76) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL633632 | 0.87 | PIK3CA (0.77) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL5556448 | 0.85 | PIK3CA (0.73) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL15602985 | 0.85 | PIK3CA (0.71) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL633416 | 0.85 | PIK3CA (0.74) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL13153411 | 0.84 | PIK3CA (0.69) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL15602934 | 0.84 | PIK3CA (0.85) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL892691 | 0.83 | PIK3CA (1.00) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 | |
| SCHEMBL15603054 | 0.81 | PIK3CA (0.79) | PIK3CAPIK3R1PIK3CDKCNH2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | PIK3CA 2/4885PIK3R1 6/4885PIK3CD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.